As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global clinical trials for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Under the terms of the definitive merger agreement between the companies, Roche will buy 89bio for about […] The post Roche to acquire 89bio, will get pegozafermin for MASH in deal appeared first on Liver Disease News.
